🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ICYMI: NTproBNP in chronic unexplained dyspnea M. Louis Handoko @rickey_carter Ryan J Tedford MD Kavita Sharma Yogesh Reddy Echocardiography Laboratory at Gunma University @bborlaugmd

🔥🔥🔥It's time to register for the 5th Annual Charleston HFpEF Conference July 18-20! If you thought it couldn't get any better, you were wrong! Check out this all-star line-up of invited faculty: media.licdn.com/dms/document/m… Robert Mentz, MD Nosheen Reza, MD, MS Muthu Vaduganathan Jeff Teuteberg

Excited to share our study “PRAISE-HFrEF” on GLP-1RA in HFrEF is accepted to the Late-Breaking Clinical Science session at ESC heart failure congress and featured in “Hottest Trials” Day 1! Thankful to collaborators Mohamad Karnib, MD Yogesh Reddy Rosita Zakeri Dr Amanda Vest

Exercise hemodynamics with bubble injection into the pulmonary artery in evaluation of hepatopulmonary syndrome and portopulmonary hypertension in hypoxemic patients with liver disease Yogesh Reddy @mayoclinicCv Fadi Adel, MD #AHAJournals ahajrnls.org/3G7n1Pd

Quick Takes: NT-proBNP Thresholds for HFpEF Diagnosis. Summary of new evidence to use NTproBNP in HFpEF evaluation in the outpatient setting. tctmd.com/videos/quick-t…

❤️‍🔥 The 5th Charleston HFpEF Conference is July 18-20. Register & book today! Don't miss insights from Robert Mentz, MD, Nosheen Reza, MD, MS, Jeff Teuteberg, Tom Cascino, MD, Greg Lewis, Andrew J Sauer MD, Yogesh Reddy, Hanna Gaggin, Monica Mukherjee MD, MPH, Muthu Vaduganathan, and more! 🔥✍️

A really important editorial in JAMA regarding the next big area of low-value, potentially harmful intervention -- on tricuspid regurgitation. Every paragraph is spot on.

Spoiler alert: In #HFpEF, it's the fat, not the sugar 🍩 Dr. Yogesh N.V. Reddy's, Yogesh Reddy, latest data crushes the myth that #diabetes alone worsens #heartfailure. jacc.org/doi/10.1016/j.… #JACC

Just published NEJM A randomized trial of Semaglutide (Ozempic) vs Tirzepatide (Mounjaro, Zepbound) at max doses demonstrates superiority of the latter for weight loss nejm.org/doi/full/10.10…

“What’s Old is New Again!” - C. Michael Gibson MD The MR / aldosterone axis remains in central focus for the *treatment* and now *prevention* of heart and kidney disease in 2025

#VICTORIA demonstrated benefits of sGC stimulator vericiguat in recent worsening HF & led to its #FDA approval in '21 New JACC Journals nationwide analysis finds use thus far has been limited jacc.org/doi/abs/10.101… Will #VICTOR (no recent worsening HF) support its broader use?

🔥HOT #HeartFailure2025 PRAISE-HFrEF 📍No suggestion of⬆️ HFH or ☠️ with GLP1-RA use at diabetes doses 📍Probable safety of GLP-1RA in clinically severe HFrEF with obesity 📍Hypothesis generating data 📍Need for RCT at weight loss doses, especially with severe obesity and/or CKD

Patient with lung disease or sleep apnea often develop precapillary PH considered group 3/4 PH. Here we show that dynamic PCWP abnormalities are very common in these pts. Trials of HFpEF therapies are needed. Circ: Heart Failure Mayo Clinic CV ahajournals.org/eprint/Y3PHYGT…

Higher HFpEF probability in group 3/4 PH is associated with dynamic PCWP abnormalities, worse functional status and quality of life. Yogesh Reddy @mayoclinicCV Jane Leopold MD Robert Frantz W. H. Wilson Tang, MD @bborlaugmd E B Rosenzweig MD Stephen Mathai Christine Jellis ahajrnls.org/4mJTDiV

🔥 #CONFIDENCE in NEJM Simultaneous initiation of #SGLT2i + #nsMRA safely and rapidly delivers in patients with CKD & T2D A new age of combination therapies has arrived in #CKM care #ERA25 nejm.org/doi/full/10.10…

Pooled analysis of obesity and kidney outcomes from 4 HFpEF RCTs now in JACC Journals 👥 n=16,919 ⬆️ waist circumference ➡️ higher kidney risk🫘🏥 ⬆️ waist-to-height ratio ➡️ higher kidney risk 🫘🏥 But not for BMI 🤔 sciencedirect.com/science/articl… Muthu Vaduganathan Tor Biering-Sørensen, MD, MSc, MPH, PhD

More evidence that not all group 1 PH is the same. In the blue journal we show how clinical gp 1 PH with high HFpEF probability is metabolomically distinct from traditional gp 1 PH, and more similar to clinical HFpEF. atsjournals.org/doi/abs/10.116… ATS Blue Journal Mayo Clinic CV